Legal News

Hypertension and hot potatoes: sartans SPC case means questions have to go to the CJEU (again…)

Published on: 10 October 2012

Table of contents

  • Original news
  • What issues did this case raise?
  • Hasn’t the CJEU already decided questions in this area before?
  • Did the judge feel the CJEU had been unclear in the past
  • What happens next?
  • What does this mean for lawyers and the pharmaceutical industry?

Article summary

IP&IT analysis: What is the scope of a combination Supplementary Protection Certificate? A closer look at the two questions referred to the CJEU in the Sanofi case and their potential to clarify the law in this area.

Popular documents